We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Humedics Co-founder Martin Stockmann Awarded with Von-Langenbeck Prize
News

Humedics Co-founder Martin Stockmann Awarded with Von-Langenbeck Prize

Humedics Co-founder Martin Stockmann Awarded with Von-Langenbeck Prize
News

Humedics Co-founder Martin Stockmann Awarded with Von-Langenbeck Prize

Read time:
 

Humedics GmbH has announced that PD Dr. Martin Stockmann, co-founder of Humedics and advisor of the management, was awarded with the highest honor of surgery in Germany, the Von-Langenbeck Prize of the German Society of Surgery (Deutsche GesellschaftfürChirurgie).

The Von-Langenbeck Prize is an award for outstanding scientific achievements in the field of surgery. Since 1954, it has been yearly awarded by the German Society of Surgery (Deutsche GesellschaftfürChirurgie).

PD Dr. Martin Stockmann from Charité - Universitätsmedizin Berlin at the Campus Virchow Hospital, Dept. of General, Visceral and Graft Surgery, received the renowned prize for the development and clinical validation of a new technique for determining liver function in surgery - the LiMAx test - and for ten years of research in the field of liver surgery and liver regeneration.

The award ceremony took place at the opening day of the 130th Congress of the German Society of Surgery in Munich. Prof. Dr. Karl-Walter Jauch, president of the society, handed over the prize and congratulated the laureate.

Stockmann said: “This prize is a great honor and pleasure for me. It is an award for more than ten years of research in the field of liver surgery and liver regeneration. I would like to take this opportunity to encourage particularly younger colleagues to engage in research. This needs superior efforts, commitment and - as the motto of this congress - passion, but it pays off.”

The award comes in a phase of the final development of the LiMAx test before regulatory product approval. In January, Humedics announced the start of a clinical phase III study.

The trial with the short title 'Fast-track LiveR' is a prospective, randomized, controlled, multi-centric, phase III study.

The main goal of this study is the early identification of low-risk patients after partial liver resection by the LiMAx test and improvements in patient management based on test results.

Advertisement